Monocytosis in patients with Coronavirus pneumonia on the background of treatment with glucocorticoids
Vestnik Rossiyskoy voyenno meditsinskoy akademii
; 4:105-112, 2021.
Article
in Russian
| GIM | ID: covidwho-2040520
ABSTRACT
Features of variation of peripheral blood leukocyte formula parameters in 86 patients with coronavirus pneumonia with leukocytosis with a background of glucocorticoid treatment were investigated. All patients were divided into 2 groups. Group 1 was 22 individuals who showed clinical signs of the bacterial infection (purulent sputum cough in combination with neutrophilic leukocytosis at hospital the admission). The 2nd group was made up of 64 patients with the glucocorticoids developed against the background of treatment with glucocorticoids (dexamethasone 20 mg/day or prednisolone 150 mg/day, intravenously for 3 days) leukocytosis >10 x109/l without signs of a bacterial infection. It was found that in patients of the 1st group compared to the 2nd group, levels of the white blood cells and neutrophils were significantly (p < 0.001) exceeded the reference values in the absence of a significant change in the number of monocytes. In patients of the 2nd group after a three-day intravenous application of the glucocorticoids on the 4th day of hospitalization, a statistically significant (p < 0.001) increase in the number of neutrophils and monocytes was established. When comparing the quantitative parameters of the leukocyte formula between the 2nd group on the 4th day of the hospitalization and the 1st group at admission, there were no differences in the level of leukocytes and neutrophils. Number of monocytes in group 2 (1.11 (0.90;1.34) x 109/l), on the contrary, statistically significantly (p < 0.001) exceeded their level in the 1st group (0.59 (0.50;0.77) x 109/l). Thus, an indicator of the number of monocytes in the peripheral blood could be a promising differential diagnostic criterion for the genesis of the leukocytosis in patients with the COVID-19. This parameter may be one of the factors influencing the decision to prescribe the antibacterial therapy.
16978-57-7; 1879-72-7; 1926-94-9; 2265-67-7; 2392-39-4; 312-93-6; 50-02-2; 55812-90-3; 7743-96-6; 1107-99-9; 125-02-0; 50-24-8; 5060-55-9; 52-21-1; 630-67-1; human diseases; coronavirus disease 2019; viral diseases; pandemics; public health; pneumonia; lungs; respiratory diseases; medical treatment; drug therapy; glucocorticoids; monocytosis; patients; peripheral blood mononuclear cells; leukocytes; clinical aspects; symptoms; sputum; cough; neutrophils; hospital admission; bacterial diseases; dexamethasone; prednisolone; monocytes; intravenous injection; differential diagnosis; diagnosis; prescriptions; antibiotics; antibacterial agents; man; Severe acute respiratory syndrome coronavirus 2; Russia; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; APEC countries; upper-middle income countries; very high Human Development Index countries; SARS-CoV-2; viral infections; lung diseases; chemotherapy; leucocytes; white blood cells; clinical picture; bacterial infections; bacterioses; bacterium; Russian Federation
Full text:
Available
Collection:
Databases of international organizations
Database:
GIM
Language:
Russian
Journal:
Vestnik Rossiyskoy voyenno meditsinskoy akademii
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS